Apimeds Pharmaceuticals US, Inc. APUS
- Market cap
- $7.6M
- P/E
- 0.0×
Follow APUS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 0.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 40.31 |
High Price
|
|||
| — | — | — | — | — | — | — | 2 | 2 | 7 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | (1) | (1) | (6) |
EBT
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (1) | (1) | (6) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (1.69) | (1.80) | (5.50) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (1.37) | (0.93) | (8.20) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | (0.05) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (1.37) | (0.93) | (8.25) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.07 | (1.72) | 140.92 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 0 | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | (1) | (1) | (9) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | (1) | (1) | (9) |
FCF
|
|||
| — | — | — | — | — | — | — | 0 | (1) | 3 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 7 |
Total Debt
|
|||
| — | — | — | — | — | — | — | 0 | 0 | (5) |
Net Debt
|
|||
| — | — | — | — | — | — | — | 0 | (1) | 153 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (638.79%) | (7.31%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | (5.00%) |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 209.62% | (7.90%) |
ROE
|
|||
Apimeds Pharmaceuticals US, Inc. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| INM InMed Pharmaceuticals Inc. | $7.7M | 0.0× | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $6.0M | 0.0× | Compare |
| GELS Gelteq Limited | $5.9M | — | Compare |
| YCBD cbdMD, Inc. | $4.8M | 55.3× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BGXXQ Bright Green Corporation | $13.9M | 0.0× | Compare |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $15.6M | 34.7× | Compare |
| SXTC China SXT Pharmaceuticals, Inc. | $3.5M | 0.0× | Compare |
| SBFM Sunshine Biopharma, Inc. | $3.3M | 0.0× | Compare |
Apimeds Pharmaceuticals US, Inc. (APUS) key facts
- Apimeds Pharmaceuticals US, Inc. (APUS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on NYSE American.
- As of September 25, 2026, APUS traded at $7.25, a market capitalization of $7.6 million.
- Return on equity was −7.90% and debt-to-equity 0.08.
Apimeds Pharmaceuticals US, Inc. (APUS) Latest News
5 May
Apimeds Pharmaceuticals US, Inc. (APUS) settles with Inscobee, enabling merger to proceed; $100 million PIPE financing to close; Lōkahi Therapeutics to advance Apitox program. Settlement clears merger path, $100M PIPE provides transformative funding, and Apitox advancement redefines APUS pipeline and prospects.
24 Mar
Apimeds Pharmaceuticals US Inc. (APUS) announces material breach of merger agreement by Inscobee Inc. (KS:006490) and Apimeds Inc., and prepares to file emergency action in Delaware Court of Chancery. Material merger breach and legal action represent major strategic disruption with potential to alter APUS trajectory and investor sentiment.
11 Feb
Apimeds Pharmaceuticals US, Inc. (APUS) and Lōkahi Therapeutics have announced a scheduled FDA Type C meeting regarding LT-100 (Apitox). This meeting is a significant step in the regulatory process for the product, which is aimed at addressing specific development issues and obtaining guidance from the FDA. The FDA Type C meeting is a critical regulatory milestone that could significantly influence the development and market trajectory of LT-100.
10 Nov
Apimeds Pharmaceuticals US, Inc. (APUS) has launched the ai² Futures Lab™ in partnership with the University of Idaho, aiming to foster innovation in biotechnology. This initiative is designed to support research and development in the biotech sector, leveraging artificial intelligence to enhance productivity and innovation. The collaboration is expected to create opportunities for students and researchers while positioning APUS as a leader in biotech advancements. The partnership with the University of Idaho and the establishment of the ai² Futures Lab™ are significant strategic moves that could enhance APUS's innovation capabilities and market positioning.
14 Oct
Apimeds Pharmaceuticals US, Inc. (APUS) has announced a collaboration with the University of Oregon’s Lundquist College of Business to launch the ai² Futures Lab™ Program. This initiative aims to leverage artificial intelligence and innovative business strategies to enhance the company's operations and market presence, reflecting a commitment to integrating advanced technologies in its business model. The collaboration with a prestigious university to develop AI-driven strategies is likely to significantly impact Apimeds' future performance and competitive positioning.
15 Sep
Apimeds Pharmaceuticals US, Inc. (APUS) has expanded its ai² Future Labs program to include students from the University of San Diego, focusing on biotech business development. This initiative aims to foster innovation and collaboration between academia and the biotech industry, providing students with hands-on experience and opportunities to contribute to real-world projects. The expansion of the program may enhance innovation and collaboration, positively influencing the company's competitive positioning.
11 Sep
Apimeds Pharmaceuticals US, Inc. (APUS) has expressed optimism regarding the FDA's draft guidance on non-opioid pain management, particularly for its Apitox program. The guidance is seen as a significant step forward in advancing the development of Apitox, which aims to provide an alternative to opioid pain relief. Apimeds believes this regulatory support will enhance its ability to bring innovative pain management solutions to market, addressing the growing need for non-opioid therapies. The FDA's draft guidance is expected to significantly influence Apimeds' strategic direction and market positioning in the non-opioid pain management sector.
25 Aug
Apimeds Pharmaceuticals US, Inc. has partnered with the University of Alabama to enhance its biotech business development through ai² Future Labs. This collaboration aims to leverage advanced technologies and research capabilities to foster innovation in the pharmaceutical sector. The partnership with a prominent university is likely to significantly enhance Apimeds' innovation capabilities and market positioning.
15 Jul
Apimeds Pharmaceuticals US, Inc. has appointed Dr. Susan Kramer as Senior Vice President of Development and Brian Peters as Head of its ai² division. Dr. Kramer, with over 30 years of experience, will oversee product development for Apitox, a bee venom-based therapeutic. Mr. Peters will lead the strategy and launch of the ai² platform. CEO Erik Emerson emphasized the importance of these appointments for strengthening operational leadership and advancing Apitox's clinical development. Both executives expressed enthusiasm for their roles and the potential of Apitox in treating osteoarthritis knee pain. The appointments of experienced leaders are likely to significantly impact product development and strategic direction, enhancing the company's competitive position.
16 May
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) closed its initial public offering on May 12, 2025, raising $13.5 million by selling 3,375,000 shares at $4.00 each. The shares began trading on May 9, 2025. D. Boral Capital LLC acted as the sole bookrunner for the offering. Proceeds will fund a Phase III clinical trial for knee osteoarthritis, a non-registered study in multiple sclerosis, product manufacturing, and general working capital. The registration statement was filed with the SEC and became effective on February 11, 2025, with a post-effective amendment on May 5, 2025. The IPO funding is expected to significantly impact Apimeds' clinical development and market positioning.
12 May
Apimeds Pharmaceuticals US, Inc. has successfully closed its initial public offering (IPO), raising significant capital to support its growth and development initiatives. The IPO marks a pivotal moment for the company, enhancing its financial position and enabling further investment in research and product development. This move is expected to bolster Apimeds' presence in the pharmaceutical market and attract investor interest. The successful IPO is a major strategic move that significantly enhances the company's financial resources and market positioning.
8 May
Apimeds Pharmaceuticals US, Inc. has announced the pricing of its initial public offering (IPO), setting the price at $15 per share. The company aims to raise approximately $100 million through the offering, which is expected to enhance its financial position and support its growth initiatives. The IPO is anticipated to attract significant investor interest, reflecting confidence in Apimeds' business model and future prospects. The IPO is a major strategic move that could significantly enhance the company's financial resources and market position.